维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Cristina Maracci"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Targeting mTOR and eIF4E:a feasible scenario in ovarian cancer therapy显示文摘Ovarian carcinoma is one of the most common causes for cancer death in women;lack of early diagnosis and acquired resistance to platinum-based chemotherapy account for its poor prognosis and high mortality rate.As with other cancer types,ovarian cancer is characterized by dysregulated signaling pathways and protein synthesis,which together contribute to rapid cellular growth and invasiveness.The mechanistic/mammalian target of rapamycin(mTOR)pathway represents the core of different signaling pathways regulating a number of essential steps in the cell,among which protein synthesis and the eukaryotic initiation factor 4E(eIF4E),the mRNA cap binding protein,is one of its downstream effectors.eIF4E is a limiting factor in translation initiation and its overexpression is a hallmark in many cancers.Because its action is regulated by a number of factors that compete for the same binding site,eIF4E is an ideal target for developing novel antineoplastic drugs.Several inhibitors targeting the mTOR signaling pathway have been designed thus far,however most of these molecules show poor stability and high toxicity in vivo.This minireview explores the possibility of targeting mTOR and eIF4E proteins,thus impacting on translation initiation in ovarian cancer,describing the most promising experimental strategies and specific inhibitors that have been shown to have an effect on other kinds of cancers.	Alice Romagnoli Cristina Maracci Mattia D’Agostino Anna La Teana Daniele Di Marino	2021	Cancer Drug Resistance2021，4，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费